The NARLAL2 Phase III Trial: Heterogeneous FDG-Guided Dose Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer Group

Ditte Sloth Møller, Jon L Andersen, Ane L Appelt, Carsten Brink, Olfred Hansen, Lone Hoffman, Nikolaj K G Jensen, Mirjana Josipovic, Azza Ahmed Khalil, Marianne Marquard Knap, Mikkel D Lund, Christina Maria Lutz, Martin Skovmos Nielsen

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article numberMINI07.03
JournalJournal of Thoracic Oncology
Volume10
Issue number9, Suppl. 2
Pages (from-to)S286
Number of pages1
ISSN1556-0864
DOIs
Publication statusPublished - 2015
EventThe World Conference on Lung Cancer - Denver, Colorado, USA, Denver, United States
Duration: 6 Sep 20159 Sep 2015
Conference number: 16th

Conference

ConferenceThe World Conference on Lung Cancer
Number16th
LocationDenver, Colorado, USA
CountryUnited States
CityDenver
Period06/09/201509/09/2015

Cite this

Sloth Møller, Ditte ; Andersen, Jon L ; Appelt, Ane L ; Brink, Carsten ; Hansen, Olfred ; Hoffman, Lone ; Jensen, Nikolaj K G ; Josipovic, Mirjana ; Khalil, Azza Ahmed ; Marquard Knap, Marianne ; Lund, Mikkel D ; Lutz, Christina Maria ; Nielsen, Martin Skovmos. / The NARLAL2 Phase III Trial : Heterogeneous FDG-Guided Dose Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer Group. In: Journal of Thoracic Oncology. 2015 ; Vol. 10, No. 9, Suppl. 2. pp. S286.
@article{088831a6662647f7870d190723fb61b8,
title = "The NARLAL2 Phase III Trial: Heterogeneous FDG-Guided Dose Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer Group",
author = "{Sloth M{\o}ller}, Ditte and Andersen, {Jon L} and Appelt, {Ane L} and Carsten Brink and Olfred Hansen and Lone Hoffman and Jensen, {Nikolaj K G} and Mirjana Josipovic and Khalil, {Azza Ahmed} and {Marquard Knap}, Marianne and Lund, {Mikkel D} and Lutz, {Christina Maria} and Nielsen, {Martin Skovmos}",
year = "2015",
doi = "10.1016/S1556-0864(16)30011-9",
language = "English",
volume = "10",
pages = "S286",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Elsevier",
number = "9, Suppl. 2",

}

Sloth Møller, D, Andersen, JL, Appelt, AL, Brink, C, Hansen, O, Hoffman, L, Jensen, NKG, Josipovic, M, Khalil, AA, Marquard Knap, M, Lund, MD, Lutz, CM & Nielsen, MS 2015, 'The NARLAL2 Phase III Trial: Heterogeneous FDG-Guided Dose Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer Group' Journal of Thoracic Oncology, vol. 10, no. 9, Suppl. 2, MINI07.03, pp. S286. https://doi.org/10.1016/S1556-0864(16)30011-9

The NARLAL2 Phase III Trial : Heterogeneous FDG-Guided Dose Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer Group. / Sloth Møller, Ditte; Andersen, Jon L; Appelt, Ane L; Brink, Carsten; Hansen, Olfred; Hoffman, Lone; Jensen, Nikolaj K G; Josipovic, Mirjana; Khalil, Azza Ahmed; Marquard Knap, Marianne; Lund, Mikkel D; Lutz, Christina Maria; Nielsen, Martin Skovmos.

In: Journal of Thoracic Oncology, Vol. 10, No. 9, Suppl. 2, MINI07.03, 2015, p. S286.

Research output: Contribution to journalConference abstract in journalResearchpeer-review

TY - ABST

T1 - The NARLAL2 Phase III Trial

T2 - Heterogeneous FDG-Guided Dose Escalation of Advanced NSCLC. A Clinical Trial by the Danish Lung Cancer Group

AU - Sloth Møller, Ditte

AU - Andersen, Jon L

AU - Appelt, Ane L

AU - Brink, Carsten

AU - Hansen, Olfred

AU - Hoffman, Lone

AU - Jensen, Nikolaj K G

AU - Josipovic, Mirjana

AU - Khalil, Azza Ahmed

AU - Marquard Knap, Marianne

AU - Lund, Mikkel D

AU - Lutz, Christina Maria

AU - Nielsen, Martin Skovmos

PY - 2015

Y1 - 2015

U2 - 10.1016/S1556-0864(16)30011-9

DO - 10.1016/S1556-0864(16)30011-9

M3 - Conference abstract in journal

VL - 10

SP - S286

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 9, Suppl. 2

M1 - MINI07.03

ER -